Study #2020-0182
A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions
MD Anderson Study Status
Enrolling
Treatment Agent
Ruxolitinib, Placebo (for Ruxolitinib)
Description
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ductal Carcinoma in Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
Study phase:
Phase II
Physician name:
Parijatham Thomas
Department:
Clinical Cancer Prevention
For general questions about clinical trials:
1-855-319-9556
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.